Table 1 Clinical characteristics of patients with hip osteoarthritis at baseline
|  | ITT population N = 97 | PP population N = 90 | X-Rays population N = 80 | P value |
|---|---|---|---|---|
Gender (Females) | 58.8% | 56.7% | 53.2% | >0.05 |
Age (Years) | 63.0 (36.0–87.0) | 63.0 (36.0–87.0) | 62.0 (36.0–87.0) | >0.05 |
BMI (kg/m2) | 25.1 (17.8–41.8) | 24.9 (17.8–41.8) | 24.9 (17.8–41.8) | >0.05 |
Disease duration (months) | 12.0 (1.0–200.0) | 12.0 (1.0–200.0) | 12.0 (1.0–200.0) | >0.05 |
WOMAC pain | 26.0 (7.0–42.0) | 25.0 (7.0–42.0) | 26.0 (7.0–42.0) | >0.05 |
WOMAC total | 120.0 (41.0–194.0) | 116.0 (41.0–194.0) | 120.0 (41.0–194.0) | >0.05 |
PGA | 7.0 (3.0–10.0) | 6.0 (3.0–10.0) | 6.0 (3.0–10.0) | >0.05 |
Previous hip steroid injection | 17.5% | 16.7% | 20.3% | >0.05 |
Previous hip HA injection | 17.5% | 17.8% | 15.2% | >0.05 |
NSAIDS regular intake | 40.0% | 42.2% | 38.7% | >0.05 |
Analgesics regular intake | 63.8% | 67.0% | 64.5% | >0.05 |